# Weissella cibaria suppresses colitis-associated colorectal cancer by modulating the gut microbiota-bile acid-FXR axis

## TL;DR

Weissella cibaria, a probiotic, reduces colorectal cancer in mice by balancing gut bacteria, bile acids, and a key receptor called FXR.

## Contribution

This study reveals a new mechanism by which Weissella cibaria suppresses colorectal cancer through the gut microbiota-bile acid-FXR axis.

## Key findings

- Weissella cibaria reshaped gut microbiota and reduced Lactobacillaceae abundance in CAC mice.
- Supplementation increased FXR expression and inhibited the NF-κB pathway, suppressing tumorigenesis.
- Modulation of bile acid metabolism by W. cibaria was central to its anti-CAC effects.

## Abstract

Gut microbiota dysbiosis critically contributes to colitis-associated colorectal cancer (CAC) pathogenesis, positioning microbial modulation as a promising therapeutic strategy. Weissella cibaria (W. cibaria) is an emerging probiotic with potential cancer-inhibiting effects. This study investigates the anti-tumorigenic potential of W. cibaria in an azoxymethane/dextran sulfate sodium-induced CAC murine model. Mice were orally administered W. cibaria every 2 days from the beginning of the model construction until the end of the experiment. The study demonstrated significant changes in the gut microbiota of CAC mice, with a significant increase in the relative abundance of Lactobacillaceae. Supplementation with W. cibaria restored the intestinal barrier and significantly reduced the relative abundance of Lactobacillaceae in the gut microbiota. The changes in the gut microbiota reduced bile salt hydrolase activity and unconjugated bile acid (BA), reversing tumorigenesis in CAC mice. Changes in intestinal BA after W. cibaria supplementation upregulated farnesoid X receptor (FXR) expression in the intestine of CAC mice and inhibited the nuclear factor kappa-B pathway. Our findings establish that W. cibaria mitigates CAC progression through the gut microbiota-BA-FXR axis, providing mechanistic evidence for its probiotic application in CAC prevention and therapy.

Chronic gut inflammation driven by microbiota dysbiosis is a pivotal contributor to colitis-associated colorectal cancer (CAC) pathogenesis. Emerging evidence highlights Weissella cibaria (W. cibaria) as a promising anti-colorectal cancer agent (Y. Du, L. Liu, W. Yan, Y. Li, et al., Sci Rep 13:21117, 2023, https://doi.org/10.1038/s41598-023-47943-7; S. Ahmed, S. Singh, V. Singh, K. D. Roberts, et al., Microorganisms 10:2427, 2022, https://doi.org/10.3390/microorganisms10122427), yet its role in CAC remains unexplored. To address this gap, we investigated the inhibitory effects of W. cibaria on CAC development in vivo and elucidated its underlying mechanisms. Our results demonstrated that oral administration of W. cibaria significantly reshaped gut microbial communities and activated bile acid (BA)-related metabolic pathways. Subsequent mechanistic studies revealed that microbiota remodeling by W. cibaria altered intestinal BA composition, particularly activating the farnesoid X receptor (FXR). FXR activation mediated by these BA shifts was identified as a critical suppressor of tumorigenesis, establishing W. cibaria as a novel probiotic capable of attenuating CAC progression. Collectively, this study uncovers a protective axis linking W. cibaria-driven microbiota modulation, BA metabolism change, and FXR-dependent tumor suppression, providing experimental evidence for probiotic-based CAC intervention strategies.